Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients

摘要: BACKGROUND. The efficacy of palliative chemotherapy was investigated in a large group patients with advanced soft-tissue sarcomas (STS) treated on routine protocols. METHODS. Patients STS who had first-line for and/or metastatic disease between 1991 and 2005 were identified from the Royal Marsden Hospital's sarcoma database. Patients Ewing sarcoma, rhabdomyosarcoma, desmoplastic small round cell tumor, gastrointestinal stromal tumors excluded study. RESULTS. In all, 488 (242 male, 246 female) fulfilled study criteria. The median age 49 years majority (83%) received disease. most common histologic subtypes leiomyosarcoma (35%) synovial (13%), liposarcoma (10%), malignant fibrous histiocytoma (10%). In 61% single-agent chemotherapy, usually doxorubicin. An objective response reported 33% (53% those sarcoma); 22% stable 45% derived ‘clinical benefit’ (objective responses + ≥6 months). Median duration 9 months posttreatment overall survival (OS) 12 months. multivariate analysis, <40 years, liposarcoma, histology found to be positive, bone involvement negative, independent prognostic factors. combination experienced longer OS than single agent. CONCLUSIONS. Palliative may beneficial approximately half STS. Synovial have better prognosis. However, poor outcome these indicates need continue search more effective agents. Cancer 2008. © 2008 American Society.